Prosecution Insights
Last updated: October 02, 2026

Examiner: WEN, SHARON X

Tech Center 1700 • Art Units: 1641 1642 1644 1684 1759

This examiner grants 57% of resolved cases

Analysis

Sharon X. Wen manages a large volume of 633 resolved cases in Art Unit 1641. The allowance rate is 56.9 percent, and the median days to allowance is 1371. These figures reflect the rigorous examination standards and long timelines typical of Tech Center 1600. Practitioners should be prepared for a prosecution cycle that lasts 1371 days and involves significant examiner scrutiny.

The interview lift of 32.6 percent is a key metric for applicants. It shows that interviews significantly enhance the 56.9 percent baseline allowance rate. Given the high case volume of 633 and the pendency of 1371 days, an interview is a recommended tactic to resolve issues and move toward a grant more effectively. The 32.6 percent lift suggests that the examiner is open to discussing technical nuances that may not be fully captured in written responses. By leveraging this lift, practitioners can improve their odds of success in a challenging docket. The examiner's extensive history provides a reliable basis for this proactive strategy, emphasizing the value of direct communication in Art Unit 1641 across the 633 resolved cases.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

56.9%
Allow Rate
-8.1% vs TC avg
665
Total Applications
+32.6%
Interview Lift
1371
Avg Prosecution Days
Based on 634 resolved cases, 2023–2026

Rejection Statute Breakdown

2.9%
§101 Eligibility
19.6%
§102 Novelty
20.9%
§103 Obviousness
32.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18286955 Glycan Targets of Serum IgG and IgM Antibodies Non-Final OA REGENTS OF THE UNIVERSITY OF MINNESOTA
17185469 METHOD FOR PREDICTING THE OUTCOME OF A TREATMENT WITH AFLIBERCEPT OF A PATIENT SUSPECTED TO SUFFER FROM A CANCER BY MEASURING THE LEVEL OF A PLASMA BIOMARKER Non-Final OA SANOFI
18416231 COMPOSITIONS FOR IMPROVING KIDNEY FUNCTION IN PATIENTS WITH HEPATORENAL SYNDROME Final Rejection Mallinckrodt Pharmaceuticals Ireland Limited
17780407 COMPOSITIONS AND METHODS FOR EPITOPE SCANNING Non-Final OA The Brigham and Women's Hospital, Inc.
16348653 COMBINED THERAPIES FOR ATHEROSCLEROSIS, INCLUDING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE Non-Final OA Amgen Inc.
13931716 METHODS FOR TREATING OR PREVENTING CHOLESTEROL RELATED DISORDERS Final Rejection AMGEN INC.
18589200 DOSE Non-Final OA AstraZeneca AB
18262843 ADJUVANT THERAPY FOR CANCER Final Rejection Iovance Biotherapeutics, Inc.
18559910 MODIFIED FCRN BINDING FRAGMENTS WITH IMPROVED HALF-LIFE Non-Final OA MedImmune, LLC
18559195 USE OF AN ANTI-CD19 ANTIBODY TO TREAT MYASTHENIA GRAVIS Non-Final OA Viela Bio, Inc

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month